Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab combined with conventional antitumor therapy for recurrent or metastatic gynecologic cancers
ChiCTR2000040223Phase 2Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Cervical Cancer (CC), endometrial cancer (EC) and ovarian cancer, sponsored by Changzhou Second People's Hospital. Primary endpoints: objective response rate and progression-free survival. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000040223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040223.